Core Viewpoint - International Medical (000516) has shown a decline in revenue and profit for the first three quarters of 2025, indicating potential challenges in its business operations and financial health [2]. Financial Performance - For the first three quarters of 2025, the company's main revenue was 2.995 billion yuan, a year-on-year decrease of 16.94% [2]. - The net profit attributable to shareholders was -294 million yuan, down 38.45% year-on-year [2]. - The net profit after deducting non-recurring items was -312 million yuan, a decline of 41.94% year-on-year [2]. - In Q3 2025, the company's single-quarter main revenue was 961 million yuan, a decrease of 18.95% year-on-year [2]. - The single-quarter net profit attributable to shareholders was -129 million yuan, a significant drop of 234.24% year-on-year [2]. - The single-quarter net profit after deducting non-recurring items was -123 million yuan, down 52.03% year-on-year [2]. - The company's debt ratio stood at 68.8%, with investment income of 20.7586 million yuan and financial expenses of 111 million yuan [2]. - The gross profit margin was 6.59% [2]. Market Activity - As of February 10, 2026, the stock closed at 4.96 yuan, with an increase of 0.4% [1]. - The turnover rate was 1.55%, with a trading volume of 341,700 hands and a transaction amount of 169 million yuan [1]. - On February 10, the net inflow of main funds was 15.2399 million yuan, accounting for 8.99% of the total transaction amount [1]. - Retail investors experienced a net outflow of 280,100 yuan, representing 0.17% of the total transaction amount [1]. Analyst Ratings - In the last 90 days, two institutions have given ratings for the stock, both recommending an increase in holdings [3]. - The average target price set by institutions over the past 90 days is 5.5 yuan [3].

证券之星消息，国际医学(000516)02月05日在投资者关系平台上答复投资者关心的问题。 投资者提问：很多人投资与你们是因为股价低，但是股价低的原因大家却不知道，资产的价格是供求关 系决定的，低价代表产品没有竞争力也没有定价权和议价能力，请问贵公司国际医学的投资价值是什 么？ 国际医学回复：您好，感谢您对公司的关注。公司的核心投资价值在于稀缺的优质医疗资产，具体体现 在以下方面：公司以大健康医疗服务和现代医学技术转化应用为主业，拥有规模化的服务体系与区域内 优质的诊疗能力；公司旗下医疗机构拥有同步国际先进水平的硬件设备（即将投用的西安国际医学中心 医院质子治疗中心是西北地区首个质子放射治疗中心）；汇聚了由各学科带头人领衔的专业团队，旗下 医院已成为6所大学的附属或教学医院；公司旗下医院"综合医疗+特色专科"的业务模式，契合多元化健 康需求。谢谢！ 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

证券之星消息，截至2026年1月28日收盘，国际医学(000516)报收于4.99元，下跌1.58%，换手率 2.17%，成交量47.81万手，成交额2.39亿元。 国际医学2025年三季报显示，前三季度公司主营收入29.95亿元，同比下降16.94%；归母净利润-2.94亿 元，同比下降38.45%；扣非净利润-3.12亿元，同比下降41.94%；其中2025年第三季度，公司单季度主 营收入9.61亿元，同比下降18.95%；单季度归母净利润-1.29亿元，同比下降234.24%；单季度扣非净利 润-1.23亿元，同比下降52.03%；负债率68.8%，投资收益2075.86万元，财务费用1.11亿元，毛利率 6.59%。国际医学（000516）主营业务：大健康医疗服务和现代医学技术转化应用。 1月28日的资金流向数据方面，主力资金净流出3864.74万元，占总成交额16.15%，游资资金净流出 149.37万元，占总成交额0.62%，散户资金净流入4014.11万元，占总成交额16.78%。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 该股最近90天内共有2家机构给出评级，增持评级2家；过 ...

证券之星消息，截至2026年1月27日收盘，国际医学(000516)报收于5.07元，下跌1.74%，换手率 3.31%，成交量73.0万手，成交额3.65亿元。 1月27日的资金流向数据方面，主力资金净流出2808.11万元，占总成交额7.7%，游资资金净流出 2325.61万元，占总成交额6.37%，散户资金净流入5133.71万元，占总成交额14.07%。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 国际医学2025年三季报显示，前三季度公司主营收入29.95亿元，同比下降16.94%；归母净利润-2.94亿 元，同比下降38.45%；扣非净利润-3.12亿元，同比下降41.94%；其中2025年第三季度，公司单季度主 营收入9.61亿元，同比下降18.95%；单季度归母净利润-1.29亿元，同比下降234.24%；单季度扣非净利 润-1.23亿元，同比下降52.03%；负债率68.8%，投资收益2075.86万元，财务费用1.11亿元，毛利率 6.59%。国际医学（000516）主营业务：大健康医疗服务和现代医学技术转化应用。 该股最近90天内共有2家机构给出评级，增持评级2家；过去9 ...

Group 1 - The core viewpoint of the article highlights the financial performance and stock activity of Guo Ji Yi Xue (International Medicine), indicating a decline in revenue and profit for the third quarter of 2025 [2] - As of January 26, 2026, the stock price closed at 5.16 yuan, down 0.96%, with a turnover rate of 3.28% and a trading volume of 722,700 hands, amounting to a total transaction value of 373 million yuan [1] - The company reported a main revenue of 2.995 billion yuan for the first three quarters of 2025, a year-on-year decrease of 16.94%, and a net profit attributable to shareholders of -294 million yuan, down 38.45% year-on-year [2] Group 2 - In the third quarter of 2025, the company recorded a single-quarter main revenue of 961 million yuan, a year-on-year decline of 18.95%, and a net profit attributable to shareholders of -129 million yuan, a significant drop of 234.24% year-on-year [2] - The company has a debt ratio of 68.8%, with investment income of 20.7586 million yuan and financial expenses of 111 million yuan, resulting in a gross profit margin of 6.59% [2] - Over the past 90 days, two institutions have given a rating of "buy" for the stock, with an average target price of 5.5 yuan [3]

Group 1 - The core point of the news is that International Medicine (000516) has seen significant share pledges from its major shareholders, indicating potential liquidity issues [1] - Shareholder Shaanxi Century Xinyuan Commercial Management Co., Ltd. has pledged a total of 75 million shares, accounting for 3.35% of the total share capital [1] - As of the announcement date, Shaanxi Century Xinyuan has pledged a total of 506 million shares, which is 82.07% of its total holdings, while shareholder Shenhua Holdings Group Co., Ltd. has pledged 45.31 million shares, representing 74.91% of its holdings [1] Group 2 - International Medicine reported a revenue of 2.995 billion yuan for the first three quarters of 2025, a year-on-year decrease of 16.94% [1] - The net profit attributable to shareholders was -294 million yuan, down 38.45% year-on-year, and the net profit after deducting non-recurring gains and losses was -312 million yuan, a decline of 41.94% [1] - In Q3 2025, the company recorded a single-quarter revenue of 961 million yuan, a decrease of 18.95% year-on-year, with a net profit of -129 million yuan, reflecting a significant drop of 234.24% [1] - The company's debt ratio stands at 68.8%, with investment income of 20.7586 million yuan and financial expenses of 111 million yuan, resulting in a gross profit margin of 6.59% [1] Group 3 - The main business of International Medicine includes health care services and the application of modern medical technology [2]

Core Viewpoint - International Medicine (000516) has experienced a decline in both revenue and net profit for the first three quarters of 2025, indicating potential challenges in its business performance [2]. Financial Performance - For the first three quarters of 2025, the company's main revenue was 2.995 billion yuan, a year-on-year decrease of 16.94% [2]. - The net profit attributable to shareholders was -294 million yuan, down 38.45% year-on-year [2]. - The net profit after deducting non-recurring items was -312 million yuan, a decline of 41.94% year-on-year [2]. - In Q3 2025, the company's single-quarter main revenue was 961 million yuan, a year-on-year decrease of 18.95% [2]. - The single-quarter net profit attributable to shareholders was -129 million yuan, a significant drop of 234.24% year-on-year [2]. - The single-quarter net profit after deducting non-recurring items was -123 million yuan, down 52.03% year-on-year [2]. - The company's debt ratio stood at 68.8%, with investment income of 20.7586 million yuan and financial expenses of 111 million yuan [2]. - The gross profit margin was 6.59% [2]. Market Activity - As of December 16, 2025, the stock closed at 4.5 yuan, down 1.1%, with a turnover rate of 0.52% [1]. - The trading volume was 113,800 hands, with a transaction amount of 51.2548 million yuan [1]. - On December 16, the net outflow of main funds was 4.082 million yuan, accounting for 7.96% of the total transaction amount [1]. - The net outflow of speculative funds was 1.8504 million yuan, representing 3.61% of the total transaction amount [1]. - Retail investors had a net inflow of 5.9323 million yuan, making up 11.57% of the total transaction amount [1]. Analyst Ratings - In the last 90 days, two institutions have given ratings for the stock, both recommending an increase in holdings [3]. - The average target price set by institutions in the past 90 days is 5.5 yuan [3].

Core Viewpoint - International Medical (000516) has experienced a decline in stock price and financial performance, indicating potential challenges in the healthcare service sector [1][3]. Financial Performance - As of December 4, 2025, the stock closed at 4.7 yuan, down 3.29%, with a trading volume of 225,400 shares and a turnover of 107 million yuan [1]. - For the first three quarters of 2025, the company's main revenue was 2.995 billion yuan, a year-on-year decrease of 16.94%, and the net profit attributable to shareholders was -294 million yuan, down 38.45% [3]. - The third quarter alone saw a main revenue of 961 million yuan, a decline of 18.95%, and a net profit of -129 million yuan, a significant drop of 234.24% [3]. Financing and Margin Trading - On December 4, 2025, the financing buy amounted to 13.736 million yuan, while financing repayment was 16.952 million yuan, resulting in a net repayment of 3.216 million yuan [2]. - The margin trading balance stood at 311 million yuan, with a short selling volume of 0 shares and a remaining short position of 10,000 shares [2]. Industry Comparison - The company's total market value is 10.523 billion yuan, significantly lower than the industry average of 18.125 billion yuan, ranking 43rd in the industry [3]. - The net asset value is 3.054 billion yuan, compared to the industry average of 5.861 billion yuan, also ranking 43rd [3]. - The company's gross margin is 6.59%, while the industry average is 36.47%, placing it 42nd in the industry [3]. Analyst Ratings - In the last 90 days, two institutions have given a rating of "buy" for the stock, with an average target price of 5.5 yuan [4].

Core Viewpoint - International Medical (000516) has shown a mixed performance in recent trading sessions, with fluctuations in stock price and varying capital flows, indicating potential volatility in investor sentiment [1][2]. Financial Performance - As of the latest report, International Medical's total market value is 10.881 billion yuan, with a net asset value of 3.21 billion yuan [3]. - The company reported a net profit of -165 million yuan, reflecting a year-on-year increase of 4.98%, while its main revenue decreased by 15.95% to 2.034 billion yuan [3]. - The gross profit margin stands at 7.8%, significantly lower than the industry average of 35.92% [3]. Capital Flow Analysis - On October 21, 2025, the stock price closed at 4.86 yuan, with a slight increase of 0.62%. The main capital flow showed a net outflow of 2.2612 million yuan, accounting for 3.83% of the total transaction volume [1][2]. - Over the past five days, the stock has experienced varying capital flows, with notable net inflows from speculative funds on certain days, while main capital has seen consistent outflows [2]. Industry Comparison - In comparison to the healthcare services industry, International Medical ranks low in several key metrics, including net profit and return on equity (ROE), with a ROE of -4.6% compared to the industry average of 2.19% [3]. - The company's price-to-earnings ratio (P/E) is -32.98, indicating a lack of profitability relative to its peers [3]. Analyst Ratings - Recently, two institutions have provided ratings for the stock, with one buy rating and one hold rating, suggesting a cautious outlook among analysts [4].

Core Viewpoint - The company positions itself as a representative comprehensive medical service listed company in the secondary market, focusing on health services and modern medical technology application [1] Group 1: Company Positioning and Services - The company has established a health service platform covering the entire lifecycle, from medical services to rehabilitation and elderly care, with a service capacity of 10,000 beds [1] - The company has built a comprehensive medical service network centered in Xi'an, rooted in Shaanxi, and radiating to the central and western regions of China [1] Group 2: Financial Performance and Shareholder Returns - The company has distributed cash dividends 16 times since its listing, totaling 576 million yuan [1] - Due to the impact of newly launched medical projects, the company's revenue has not yet covered operational costs, resulting in net losses and no cash dividends being distributed [1] - The company has been actively repurchasing shares and implementing stock incentives for core teams, signaling confidence to the market [1] Group 3: Communication with Investors - The company emphasizes communication with investors through performance briefings, establishing an investor relations public account, and organizing activities for investors to visit the company [1]